Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study

Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901-Beta SARS-CoV-2 Vaccine in Adults: A Phase I, Prospective, Randomized, Open-Labeled Study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on variant strains have been in use as booster doses to update immunity against circulating variants. Here we present the results of a phase one prospective, randomized, and open-labeled trial to study the safety and immunog...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccines (Basel) 2023-12, Vol.11 (12), p.1798
Hauptverfasser: Lien, Chia En, Liu, Ming-Che, Wang, Ning-Chi, Liu, Luke Tzu-Chi, Wu, Chung-Chin, Tang, Wei-Hsuan, Lian, Wei-Cheng, Huang, Kuan-Ying A, Chen, Charles
Format: Artikel
Sprache:eng
Schlagworte:
Adults
Aluminum
Antibodies
booster vaccination
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
Demographics
Enzymes
Immunogenicity
Immunoglobulins
Intervention
Methods
MVC-COV1901
Pandemics
Proteins
Safety
SARS-CoV-2 vaccine
Severe acute respiratory syndrome coronavirus 2
Spike protein
Statistical analysis
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on variant strains have been in use as booster doses to update immunity against circulating variants. Here we present the results of a phase one prospective, randomized, and open-labeled trial to study the safety and immunogenicity of a booster dose consisting of a subunit vaccine based on the stabilized prefusion SARS-CoV-2 spike protein, MVC-COV1901, or its Beta version, MVC-COV1901-Beta. Participants aged ≥18 and
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11121798